Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA’s Califf Responds To, And Deflects, Senators’ Mifepristone Questions

Executive Summary

The Senate Appropriations Subcommittee hearing was called to discuss the agency’s FY 2024 budget request, but several committee members wanted to talk about the pending Supreme Court decision on the medication abortion drug.

You may also be interested in...

Supreme Court’s Stay Of Mifepristone Ruling Gives FDA Respite For Next Round

Medication abortion pill can remain on the market under current conditions until appeal on the merits of the preliminary injunction is decided. Justice Alito dissents, noting that FDA could exercise its enforcement discretion to prevent harm to mifepristone manufacturer Danco.

PhRMA Jumps Into Battle Over Mifepristone Regulation With Supreme Court Filing

After sitting out the initial rounds, trade group backs FDA’s decisions on the medication abortion pill and asks Supreme Court to stay Texas district court ruling suspending the drug’s approval.

FDA's Woodcock To Supreme Court: Mifepristone Ruling Will Create 'Significant Chaos’

Supreme Court stays Texas district court’s order until 19 April. FDA’s deputy principal commissioner says if it goes into effect, sponsors will have to submit additional applications, prescribers may need to be recertified, and FDA will have to reinstate higher dosing regimen.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts